Drug Maker Structure Therapeutics Offers Big Bet on ‘Diabesity’ With IPO

One of the first major biotech deals of the new year is offering investors a big bet on diabetes and obesity treatments. Drug developer Structure Therapeutics has set terms for a deal that aims to comfortably clear the $100 million mark. On Monday, January 30, Structure Therapeutics announced it…#drug #jefferies #svbleerink #guggenheimsecurities #bmocapitalmarkets #federalreserve #phase1b #gsbr1290 #phase2a #raymondstevens
Source: Reuters: Health - Category: Consumer Health News Source Type: news